Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.
3 reports, 2 independent
Updated Aug 27
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.Sub-event
Amgen and AstraZeneca collaborate on Phase 3 CROSSING trial for TEZSPIRE.1 source
Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company